Coeptis Therapeutics Files 8-K with Bylaw Amendments
Ticker: COEPW · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1759186
Sentiment: neutral
Topics: corporate-governance, filing-update
Related Tickers: COEP
TL;DR
COEP filed an 8-K for bylaw changes, check for governance updates.
AI Summary
On December 26, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report detailing amendments to its articles of incorporation and bylaws. The company also reported on other events and filed financial statements and exhibits. This filing follows the company's previous name change from Bull Horn Holdings Corp. on November 15, 2018.
Why It Matters
This filing indicates corporate governance updates for Coeptis Therapeutics, which could impact its operational structure and shareholder rights.
Risk Assessment
Risk Level: low — The filing primarily concerns administrative and corporate governance updates, not significant financial or operational events.
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- Bull Horn Holdings Corp. (company) — Former Company Name
- December 26, 2024 (date) — Date of Report
- November 15, 2018 (date) — Date of Name Change
FAQ
What specific amendments were made to Coeptis Therapeutics' articles of incorporation and bylaws?
The filing indicates amendments were made, but the specific details of these changes are not provided in the summary text.
What were the 'Other Events' reported by Coeptis Therapeutics on December 26, 2024?
The provided text mentions 'Other Events' as an item information category but does not specify what those events were.
What financial statements and exhibits were filed with this 8-K?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the specific contents are not detailed in the provided text.
When did Coeptis Therapeutics Holdings, Inc. officially change its name from Bull Horn Holdings Corp.?
The company's name was changed from Bull Horn Holdings Corp. to Coeptis Therapeutics Holdings, Inc. on November 15, 2018.
What is the primary business of Coeptis Therapeutics Holdings, Inc.?
Coeptis Therapeutics Holdings, Inc. is in the business of Biological Products (No Diagnostic Substances), with a Standard Industrial Classification code of 2836.
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2024-12-27 16:45:08
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
- $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
- $0 — nding shares of common stock, par value $0.0001, following authorization by its Bo
Filing Documents
- coeptis_8k.htm (8-K) — 35KB
- coeptis_ex9901.htm (EX-99.1) — 11KB
- coeptis_ex9902.htm (EX-99.2) — 12KB
- 0001683168-24-009012.txt ( ) — 280KB
- coep-20241226.xsd (EX-101.SCH) — 3KB
- coep-20241226_def.xml (EX-101.DEF) — 26KB
- coep-20241226_lab.xml (EX-101.LAB) — 36KB
- coep-20241226_pre.xml (EX-101.PRE) — 25KB
- coeptis_8k_htm.xml (XML) — 6KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year In connection with the Reverse Split described in Item 8.01 below, on December 26, 2024, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the " Certificate of Amendment "). A copy of the Certificate of Amendment is included as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events On December 27, 2024, Coeptis Therapeutics Holdings, Inc. (the "Company") announced that it will proceed with a 1-for-20 reverse stock split (the "Reverse Split") of its issued and outstanding shares of common stock, par value $0.0001, following authorization by its Board of Directors and majority shareholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40 (the "Reverse Split Range"), with the Board having the discretion as to whether or not the Reverse Split is to be effected, and the exact ratio to be set at a whole number within the Reverse Split Range. A copy of the press release is included as Exhibit 99.2 to this Current Report on Form 8-K. The Reverse Split will be effective after the market closes on December 30, 2024, and will begin trading on a post-split basis on the Nasdaq Capital Market at market open on December 31, 2024. In conjunction with the Reverse Split, the CUSIP number will be changed to 19207A 207. There will be no change to the par value of the Company's common stock. The Reverse Split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares with the exception of those holders of fractional shares. No fractional shares will be issued in connection with the Reverse Split. The Company will issue one whole share of common stock to any stockholder who would have been entitled to receive a fractional share of common stock due to the Reverse Split. Each holder of common stock will hold the same percentage of the outstanding common stock immediately following the Reverse Split as that stockholder did immediately before the Reverse Split, except for adjustments due to the additional net share fraction that will need to be issued as a result of the treatment of fractional shares. Proportionate adjustments will be made to the number of shares of common stock underlying the Company's outstanding equity awards, warran
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No . Description 99.1 Certificate of Amendment of Amended and Restated Certificate of Incorporation dated December 26, 2024 99.2 Press Release dated December 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: December 27, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3